Unknown

Dataset Information

0

Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.


ABSTRACT: Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose co-transporter 2 (SGLT2) inhibitors are frequently used in combination for the treatment of type 2 diabetes mellitus (T2DM). We examined the efficacy and safety of teneligliptin (a DPP-4 inhibitor) added to canagliflozin (an SGLT2 inhibitor) monotherapy in Japanese patients with poorly controlled T2DM as part of the development of a fixed-dose combination of teneligliptin and canagliflozin. Japanese patients treated with canagliflozin (100 mg) for ?12 weeks were randomized to receive add-on teneligliptin (20 mg; C + T group) or placebo (C + P group) for 24 weeks. The primary endpoint was change in glycated haemoglobin (HbA1c) from baseline to Week 24. The between-group differences in reductions from baseline to Week 24 were significantly greater in the C + T group for HbA1c (-0.94%; P < .001). The incidence of adverse events was similar in both groups (55.8% and 49.4% in the C + T and C + P groups, respectively). No episodes of hypoglycaemia were reported. Teneligliptin added to ongoing canagliflozin monotherapy improved glycaemic control and was well tolerated in Japanese patients with inadequately controlled T2DM.

SUBMITTER: Kadowaki T 

PROVIDER: S-EPMC5846888 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.

Kadowaki Takashi T   Inagaki Nobuya N   Kondo Kazuoki K   Nishimura Kenichi K   Kaneko Genki G   Maruyama Nobuko N   Nakanishi Nobuhiro N   Gouda Maki M   Iijima Hiroaki H   Watanabe Yumi Y  

Diabetes, obesity & metabolism 20170915 2


Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose co-transporter 2 (SGLT2) inhibitors are frequently used in combination for the treatment of type 2 diabetes mellitus (T2DM). We examined the efficacy and safety of teneligliptin (a DPP-4 inhibitor) added to canagliflozin (an SGLT2 inhibitor) monotherapy in Japanese patients with poorly controlled T2DM as part of the development of a fixed-dose combination of teneligliptin and canagliflozin. Japanese patients treated with canagliflozin  ...[more]

Similar Datasets

| S-EPMC5484989 | biostudies-literature
| S-EPMC4912792 | biostudies-literature
| S-EPMC8029565 | biostudies-literature
| S-EPMC8015819 | biostudies-literature
| S-EPMC5069603 | biostudies-literature
| S-EPMC3988010 | biostudies-literature
| S-EPMC4021346 | biostudies-literature
| S-EPMC3906835 | biostudies-literature
| S-EPMC5724659 | biostudies-literature
| S-EPMC5934244 | biostudies-literature